Document is current
Any future updates will be listed below
-
Authors
Krueger, James https://orcid.org/0000-0002-3775-1778
Puig, Lluís https://orcid.org/0000-0001-6083-0952
Thaçi, Diamant https://orcid.org/0000-0001-8513-550X
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Universität zu Lübeck
- License Information
-
More Information
Article History
Accepted: 14 November 2021
First Online: 21 January 2022
Declarations
:
: This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.
: Medical writing support was funded by Boehringer Ingelheim.
: James Krueger has received grants from and been an investigator for Boehringer Ingelheim; received personal fees from AbbVie, Baxter, Biogen Idec, Delenex Therapeutics, Kineta, Sanofi, Serono, and XenoPort; and received grants from Amgen, Bristol Myers Squibb, Dermira, Innovaderm Research, Janssen, Kadmon, Kyowa Kirin, Eli Lilly, Merck, Novartis, Parexel, and Pfizer. Lluís Puig has received grants/research support or participated in clinical trials (paid to institution) from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB; received honoraria or consultation fees from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, LEO Pharma, Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB; and participated in company-sponsored speaker’s bureau for Celgene, Janssen, Lilly, Novartis, and Pfizer. Diamant Thaçi has served as a consultant, advisory board member, and/or investigator for Pfizer, AbbVie, Almirall, Amgen, Beiersdorf, Bristol Myers Squibb, Boehringer Ingelheim, Dainippon Sumitomo Pharma, Eli Lilly, Galapagos, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Maruho, Medac, MorphoSys, Novartis, Regeneron, Samsung, Sandoz, Sanofi, Sun Pharma, and UCB.
: Not applicable.
: Not applicable.
: The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of each review article was at the direction of the authors, who provided guidance to OPEN Health Communications on the content of the article, critically revised the work, and approved the content for publication.
: Not applicable.
: Not applicable.
: Not applicable.
